Evidence for off-target effects of live Shingles vaccination against all-cause death and infection-associated hospitalisation in older adults in England: a population-based cohort study

Klara Doherty, MBChB[1,2,3]; Natalie E.R. Beveridge, DPhil[1,3]; Laura Bonnett, PhD[4]; Valerie Decraene, PhD[1,5]; Caroline Jeffery, PhD[1]; Marc Henrion, PhD[2,7]; Daniel Hungerford, PhD[1,7*]; Neil French, PhD FRCP[1,3*]

1. The Centre for Global Vaccine Research, Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, UK
2. Liverpool School of Tropical Medicine, Pembroke Place, Liverpool UK
3. Royal Liverpool and Broadgreen University Hospitals NHS Trust, members of Liverpool Health Partners, L7 8XP, Liverpool, UK
4. Department of Health Data Science, Institute of Population Health, University of Liverpool, members of Liverpool Health Partners, Liverpool L69 3GL, UK
5. Field Services, United Kingdom Health Security Agency, Liverpool L3 1DS, UK
6. Malawi-Liverpool Wellcome Research Programme, Chichiri, Blantyre 3, Malawi
7. National Institute for Health and Care Research Health Protection Research Unit in Gastrointestinal Infections at the University of Liverpool, Liverpool L69 3GL, UK

*Joint senior authors, contributed equally

Corresponding Author: Professor Neil French, Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, The Ronald Ross Building, 8 West Derby Street, Liverpool, L69 7BE
E: N.French@liverpool.ac.uk | T: 0151 795 9630

Abstract:

Background: Off-target, heterologous, or non-specific live vaccine effects have been described in paediatric populations. We investigated whether off-target effects are observed in older adults with live shingles (*Zostavax®*) immunisation.

Methods: A population-based cohort study was performed using primary- and secondary-care data from the Clinical Practice Research Datalink in England. Vaccine eligible individuals aged 70 years and over who had received pneumococcal immunisation were studied. All-cause death, all-cause hospitalisation, and infection-associated hospitalisation rates were compared between vaccinated and unvaccinated groups using time-to-first-event Cox regression and a time-varying coefficient model, while adjusting for confounding.

Findings: Between September 2013 and June 2019 375 048 participants aged 70 years and over were identified, of which 56% had live shingles vaccine exposure. All-cause death rate was 18·9 per 1000 person-years, all-cause hospitalisation rate was 214 per 1000 person-years, and infection-associated hospitalisation rate was 48·4 per 1000 person-years. Live shingles vaccine exposure was associated with a reduction in all-cause death (adjusted hazard ratio 0·68; 95% confidence interval 0·67, 0·70) and infection-associated hospitalisation (adjusted hazard ratio 0·83; 95% confidence interval 0·81, 0·84). Protective vaccine effects were observed for at least five years post-immunisation. No protective vaccine effect was observed against all-cause hospitalisation.

Interpretations: Receipt of live shingles vaccine associates with lower mortality and morbidity in older adults in England. The potential for causal linkage should be validated in robust prospective studies, with major implications for national immunisation policies.

Funding: No specific funding for this project. KD was supported by an NIHR academic clinical fellowship.

Background

The live shingles vaccine (*Zostavax®,* Merck) has been routinely offered to adults in England aged 70

years and over since 1st September 2013. It has resulted in a 64% reduction in herpes zoster disease

and 81% reduction in post-herpetic neuralgia in the vaccinated population.[1] As well as disease-

specific protection, live vaccines have been observed to provide wider protection from other

infectious pathogens and from malignancies, which has been termed heterologous, non-specific, or

off-target vaccine effects. In paediatric populations Bacillus Calmette–Guérin (BCG) and measles

vaccination has been associated with reduced all-cause mortality in low-income settings,[2,3] and

reduced hospitalisation and illness in high-income settings.[4–6] The precise mechanisms of these

effects remains unclear but may include beneficial programming of the innate immune system, as

well as cross-reactivity and bystander activation of the adaptive immune system.[7]

Whether these heterologous live vaccine effects are observed in older adults has not been assessed.

Evidence of heterologous live vaccine effects in older adults would change cost-effectiveness

evaluation and have important policy implications. However, older age is associated with

immunosenescence which may mean live vaccines do not have the same broad effect.[7] An

association between the live shingles vaccine and protection from dementia and cardiovascular

disease has been demonstrated but is considered a result of direct protection from varicella zoster

virus effects, rather than an off-target effect.[8,9]

The aging population in the UK and other settings worldwide is driving a growing demand on

healthcare systems.[10] There is an urgent need to develop cost-effective interventions for older adults

to alleviate this health-system burden. The only live vaccine that has been used extensively in the

older adult population in the UK has been the live shingles vaccine (*Zostavax®*). As a vaccine given to

control a chronic established viral infection it is somewhat different to the assessment of the

measles and BCG vaccines in children but nevertheless provides an opportunity to look for health

benefits beyond the immediate prevention of shingles. We have used as population-based cohort

study to evaluate the effect of live shingles vaccine exposure on all-cause mortality and

hospitalisation in over 70-year-olds in England.

Methods

Data Source

The Clinical Practice Research Datalink (CPRD) is a longitudinal database of primary health-care data

submitted by participating practices across the UK.[11] CPRD contains medical records for

approximately 18 million currently registered patients and is representative of the population of UK.

Unless patients opt out, anonymised demographic and medical data is collected monthly and quality

checked at individual and practice level to ensure validity of these data. This study uses the CPRD

Aurum database generated from EMIS® electronic patient records which is anonymously linked to

secondary-care data through Health Episode Statistics (HES) and to patient- or practice-level

socioeconomic data through the Index of Multiple Deprivation (IMD).[11] As HES linkage was required,

only participants in England could be included.

Study population

Individuals aged 70 years and over between 1st September 2013 and 30th June 2019 were extracted

from CPRD. To ensure anonymity CPRD only provides year of birth so all participants were given the

birthday 1st July for analysis purpose. Only those eligible for live shingles vaccination (birth year 1933

to 1948) were included, and all participants with an immunocompromising condition which would

make them ineligible for live vaccination were excluded (supplementary table 1 for

immunocompromising conditions). Vaccination with the live shingles vaccine was identified from

CPRD Aurum observation and drug files (supplementary table 2 for vaccination codes). To minimise

the impact of inherent differences in health-seeking behaviours between vaccinated and

unvaccinated populations we limited participants to those who had demonstrated engagement with

the UK vaccination schedule and had been immunised with the pneumococcal polysaccharide

vaccine (PPV23) which is offered from 65-years of age.[12,13] Participants were excluded if they had

received the lower-dose varicella zoster vaccine (*Varivax®*) (supplementary table 3); if they have

received multiple doses of the live shingles vaccine; if they had received the live shingles vaccine

prior to age 70 years; or if they had received the live shingles vaccine prior to September 2013

(supplementary figure 1 for study population creation). Participants were only included if they met

the CPRD quality standards of valid age, sex, death date, registration, and clinical event dates. To

ensure accuracy of the data, participants were excluded if they have received the live shingles

vaccine prior to their CPRD current registration date (date from which the patient is continuously

registered at a medical practice), plus 28 weeks to prevent historical events being recorded as

current.[14]

<u>Outcome events: All-cause death, all-cause hospitalisation, and infection-associated hospitalisation</u>

Death during the study period was identified from death date recorded in CPRD patient files.

Hospitalisation events were identified from HES Admitted Patient Care (APC) database which is

linked to CPRD data via a unique patient identifier. Infection-associated hospitalisation events were

identified through International Classification of Disease and Health Related Problems Revision 10

(ICD-10) coding of primary and secondary discharge diagnoses held by HES using previously defined

infectious disease diagnoses.[15]

<u>Other variables</u>

Participant baseline age and sex were identified from CPRD. Participants' baseline comorbidity

status was represented by the 2011 updated version of the Charlson Comorbidity Index; a

continuous scale which predicts mortality in high-income settings.[16] Participants were classified at

baseline as having ever smoked or having never smoked as ex-smoking status cannot be accurately

defined in CPRD.[17] Socioeconomic status was defined by the patient-level English IMD 2015 quintile

and was included in the model as an ordered categorical variable. If patient-level IMD quintile was

not available, then practice-level IMD quintile was substituted. Influenza and pneumococcal disease

are major causes of mortality and hospitalisation in the study population.[18] Annual influenza vaccine

exposure was included as a continuous variable by dividing the total number of influenza vaccines

received by follow-up time in years. PPV23 immunisation status was included as a time-varying

covariate. Finally, a continuous variable was generated to reflect participants' rate of consultation at

their medical practice preceding study-entry as this may affect their likelihood of receiving the live

shingles vaccine, and their risk of hospitalisation and death. This was generated by calculating the

number of weeks in which a participant had contact with their medical practice in the two years

preceding the year of study-entry divided by the number total number of weeks (104 weeks).[19]

<u>Statistical analysis: Risk of outcome associated with vaccine exposure</u>

Time-to-first-event analysis was performed to compare outcome events between participants who

had received live shingles vaccination and those who had not. Individuals entered the study at age

69·5 years or on 1st September 2013 (whichever was later) and live shingles vaccination was included

as a time-varying exposure. Censoring occurred at outcome event, death, transfer out of medical

practice, medical practices' last-collection-date, or study-end date. A multi-level Cox proportional

hazards model was used to compare the hazard ratio (HR) between those exposed and those

unexposed to shingles vaccination for each outcome, after it was confirmed that the data did not

violate the proportional hazards assumptions (survival plots did not overlap, Schoenfeld residuals

were not significantly correlated over time, and log-log survival curves were parallel (supplementary

figure 2)). The model was adjusted for baseline age, sex, smoking status, socioeconomic quintile,

mean influenza vaccinations per year, consultation rate at medical practice in preceding two years,

and updated Charlson comorbidity score. A random intercept was added for participant medical

practice. A linear relationship between age and outcome rate was confirmed to ensure this variable

did not require transformation (supplementary figure 3). Analyses were conducted using R Studio

(2023.12.1 Build 402).

<u>Statistical analysis: Risk of outcome over follow-up time associated with vaccine exposure</u>

To capture vaccine effect over time we modelled hazard using a time-varying coefficient model.[20]

Cubic b-splines were used with yearly internal knots up to five years and performed better than

other spline models (including unspecified knot locations) by Akaike's Information Criterion and

visualisation plots.[21] In the time-varying coefficient model the random intercept for participants'

medical practice was removed due to convergence failure secondary to low participant numbers in

some medical practices.

<u>Statistical analysis: Sensitivity analyses</u>

Several pre-defined sensitivity analyses were performed including: Exclusion of participants with less

than one year follow-up who were potentially deemed too frail for live immunisation; exclusion of

participants who received the live shingles vaccine prior to the PPV23 vaccine against UK vaccination

policy; exclusion of participants with an outcome event within 30 days of a varicella-zoster disease

event to exclude on-target vaccine effects; and exclusion of participants with an outcome event

within 14 days of immunisation. Analysis of risk of death and hospitalisation in participants stratified

by sex, age, comorbidity, socioeconomic status, smoking status, and influenza vaccine exposure was

performed.

Results

Study Population

The study included 375 048 participants aged over 70 years between 1st September 2013 and 30th

June 2019 identified from CPRD Aurum databases, giving a total person-time of 1 609 861 years. A

total of 209 382 (56%) participants received the shingles vaccine during the study period. The same

proportion of individuals were vaccinated in each full year of follow up (supplementary figure 4).

Participants were registered at 886 GP medical practices from all ten of England's 2019 geographical

regions. Shingles vaccine coverage ranged from 50% in London to 60% in the East Midlands. Baseline

characteristics of the study population are illustrated in table 1 demonstrating relatively balanced

comparison groups in terms of sex, consultation rate at primary healthcare, geographical region of

residence, influenza vaccine exposure, and PPV23 exposure at baseline. Participants who went on to

have a live shingles vaccine were slightly younger at study entry (median age 69·5 (IQR 69·5 - 72·2)

compared to 72·2 (IQR 69·5 - 74·2) in individuals who remained unvaccinated). Slightly fewer

participants in the live shingles vaccine exposed group had a comorbidity at baseline (58·6%; n=122

731 compared to 63·1%; n=104 650) Median follow up time was 5·28 years (IQR 2·50 – 5·83 years) in

the unexposed group and 4·91 years (IQR 3·50 – 5·83 years) in the live shingles vaccine exposed

group. Median time to receiving the live shingles vaccine from study entry was 1·19 years for the

exposed group.

Risk of all-cause death, all-case hospitalisation, and infection-associated hospitalisation with live

shingles vaccine exposure

The rate of all-cause death was 18·9 per 1000 person-years of observation (pyo) and was lower in

the vaccine exposed group (14·6 per 1000 pyo compared to 21·2 per 1000 pyo in vaccine

unexposed). After adjustment the hazard ratio (aHR) of all-cause death following shingle vaccine

exposure was 0·68 (95% confidence interval (CI) 0·67, 0·70) (Table 2). The survival curves

demonstrate a divergence of survival within one year of study entry (Figure 1). Visualisation of

hazard over follow-up time using the time-varying coefficient model confirms the vaccine protective

effect against death is highest within one year of immunisation and attenuates towards the null over

follow-up time (Figure 2). The rate of all-cause hospitalisation was 214 per 1000 pyo and no

difference in hospitalisation rate was detected between vaccine exposed and unexposed

participants (aHR 0·99 (95% CI 0·98, 1·00)) (Table 2, Figure 1, Figure 2). The rate of infection-

associated hospitalisation was 48·4 per 1000 pyo and live shingles vaccine exposure was associated

with a lower risk of infection-associated hospitalisation after adjusting for confounding (aHR 0·83

(95% CI 0·81, 0·84)). The protective effect against death and infection-associated hospitalisation

persisted for at least five years post-immunisation (Figure 2).

Sensitivity analyses

No difference in aHRs were observed with exclusion of individuals with less than one year follow up,

PPV23 after live shingles vaccination, varicella-zoster associated outcome event, nor live shingle

vaccine associated outcome event (supplementary tables 4-7). Stratified analysis demonstrated a

stronger protective effect in participants younger at baseline against death (aHR for 70- to 74-year-

olds 0·58 (95% CI 0·56, 0·60) versus aHR for age 75 years and over 0·65 (95% CI 0·63, 0·68)) and

infection-associated hospitalisation (aHR for 70- to 74-year-olds 0·76 (95% CI 0·74, 0·77) versus aHR

for age 75 years and over 0·81 (95% CI 0·78, 0·83)). A stronger protective effect was demonstrated in

the most comorbid participants against death (aHR in least comorbid 0·72 (95% CI 0·69, 0·76) versus

most comorbid 0·55 (95% CI 0·43, 0·70)), hospitalisation (aHR in least comorbid 1·00 (95% CI 0·99,

1·02) versus most comorbid 0·79 (95% CI 0·65, 0·97)), and infection-associated hospitalisation (aHR

in least comorbid 0·84 (95% CI 0·82, 0·86) versus most comorbid 0·63 (95% CI 0·49, 0·81))

(supplementary tables 8-10).

Discussion

In this study live shingles vaccine exposure in older adults in England was associated with a 32%

reduction in death and a 17% reduction in infection-associated hospitalisation which persisted for at

least five years following immunisation. No protective vaccine effect was detected against all-cause

hospitalisation. The all-cause hospitalisation data included both elective and acute admissions and

we did not have access to data to distinguish between these. As elective admissions in England far

exceed emergency admissions, this may mask a vaccine effect on emergency admissions, which

would be more evident in infection-associated admissions which are primarily emergency.

As an observational study there is major potential for confounding. Inherent differences in health-

seeking behaviours and risk of disease has been described between vaccinated and unvaccinated

populations, which can influence observed vaccine effectiveness.[12] A number of strategies were

adopted in this study to account for this including the use of a study population which had all

engaged in the UK immunisation schedule by receiving PPV23 immunisation, and adjusting for

influenza vaccine exposure in the survival analysis. Influenza is a common cause of death and

hospitalisation in older adults, but incorporating flu vaccine status also helps control for health-

seeking behaviour. The difference in baseline vaccine exposure observed between the comparisons

groups was relatively small. Live vaccines are not recommended for immunocompromised

individuals due to the risk of adverse effects from the vaccine.[13] It is possible that the unvaccinated

group in this study included more frail individuals. While individuals with a defined and recorded

immunocompromising condition were excluded from this study, this may not cover individuals who

were deemed too vulnerable or frail by the clinician for live immunisation but who do not have a

specific immunocompromising condition. Sensitivity analysis removed individuals who died in the

first year of follow-up and were possibly deemed too frail for live shingles immunization. This did not

alter the estimate substantially. Imbalances at baseline were noted for deprivation and comorbidity.

Stratified analysis did not fundamentally alter the associations.

The study relied on secondary data recorded by healthcare workers for healthcare provision and was

not originally intended for use in research. CPRD includes internal checks to ensure validity of data

including valid age and date of clinical events.[11] Date of death recorded in CPRD has been found to

largely correspond to Office of National Statistics death records and the broad and non-specific

nature of the all-cause hospitalisation outcome limits the risk of misclassification of outcome.[22]

Study follow-up time was limited to when participants were continuously registered at the same GP

to limit misclassification of variables. The use of the secondary data source also has significant

strengths as it facilitates a large sample size from a dataset which is representative of the English

population.[11]

This is the first study to evaluate the effect of the live shingles vaccine (*Zostavax®*) in older adults on

mortality and hospitalisation. The results are consistent with two recent studies estimating a

substantial reduction in dementia diagnosis associated with live shingles vaccination in a Welsh

population and a 23% reduction in cardiovascular disease in South Korea which persisted for eight

years following immunisation.[8,9,23] In the case of the dementia association this has also been seen

with the recombinant non-live vaccine which may suggest an underlying mechanism linked to

protection from the direct consequences of varicella zoster virus, or heterologous effects of non-live

vaccines.[9,23] The reduction in cardiovascular deaths was hypothesized as a direct effect through the

prevention of varicella-zoster associated cardio-vascular toxicity, however the large effect size raises

the possibility of a broader off-target beneficial effect.

The reduction in infection-associated acute hospitalisations would be consistent with the prevailing

ideas on the mechanism of heterologous vaccine effects, namely programming of the innate and

adaptive immune response to provide a more protective and regulated response to

inflammation.[24,25] Whilst there has been extensive study of the varicella zoster targeting immune

response of these vaccines, immunological study of off target responses may provide an efficient

means of determining whether biologically supportive differences exist post live shingles vaccine.[26]

The findings in this study suggests that despite the impairment of the immune system associated

with older age, live vaccines still elicit heterologous immune-boosting effects which protect from

common infectious causes of morbidity and mortality. We cannot exclude residual confounding in

this study and therefore doubt will remain about the effect and scale. However the size of the

findings and the emergence of other evidence argues strongly for the need to understand any

potential effects better. This study advocates for the incorporation of robust but practical

experimental design into vaccine policy and vaccine implementation. For example, phased or cluster

randomised roll-out of new vaccines or during age de-escalation to allow robust evidence

generation. An immediate question is whether there is any difference between live and recombinant

shingles vaccine. The introduction of the two-dose inactivated recombinant Shingrix® vaccine into

the UK schedule from 2023 provides a low-cost natural experiment to answer this question and will

be immediately relevant for policy.

In conclusion, this study offers evidence for heterologous, off-target effects of live shingles vaccine

exposure in individuals aged 70-years and over. These findings should be considered when

evaluating the cost-effectiveness of live vaccines and shingles vaccination policy in the growing older

adult population, and advocates for experimental design in vaccination policy and implementation.

List of Abbreviations

95%CI = 95% confidence interval

aHR = Adjusted hazard ratio

BCG = Bacillus Calmette–Guérin vaccine

CPRD = Clinical Practice Research Datalink

HES = Health Episode Statistics

HR = Hazard ratio

IMD = Index of Multiple Deprivation

ICD-10 = International Statistical Classification of Diseases and Related Health Problems Revision 10

IQR = Interquartile range

NIHR = National Institute of Health Research

PPV23 = 23-valent pneumococcal polysaccharide vaccine (Pneumovax™, Merck & Co®)

Footnotes

Acknowledgements: This study is based on data from the Clinical Practice Research Datalink (CPRD).
CPRD is jointly sponsored by the Medicines and Healthcare products Regulatory Agency and the
National Institute for Health Research (NIHR), as part of the Department of Health and Social Care.
This work uses data provided by patients and collected by the National Health Service as part of their
care and support. We would like to acknowledge all the data providers and general practices that
made the anonymised data available for research. This study would not have been possible without
the wider CPRD team at University of Liverpool including Pieta Schofield. We are indebted to
Professor Peter Smith, London School of Tropical Medicine and Hygiene for making suggestions on
earlier drafts of this manuscript. The views expressed are those of the author and not necessarily
those of the NIHR, the Department of Health and Social Care or Public Health England.
Contributors: NF, DH, NB, KD conceived of and designed the study. DH, KD acquired the data; KD
analysed the data with support from DH, CJ, LB, MH, NF, and all authors interpreted the output; KD
wrote the first draft of the report; and all authors reviewed the draft and final manuscript.
Competing interests: NF and DH have previously received research-initiated and industry-initiated
research grant support from GlaxoSmithKline (GSK) Biologicals for evaluation of rotavirus vaccination
in the UK. DH has also received grants from GSK, Sanofi Pasteur, and Merck & Co (Kenilworth, New
Jersey, USA) for rotavirus strain surveillance. KD, NB, LB, VD, CJ have nothing to disclose.
Funding: There was no direct funding for this project. KD was funded by a National Institute for
Health and Care Research (NIHR) Academic Clinical Fellowship (ACF-2017-07-004). DH was funded by
a NIHR Post-doctoral Fellowship (PDF-2018-11-ST2-006). DH is affiliated to the National Institute for
Health and Care Research Health Protection Research Unit (NIHR HPRU) in Gastrointestinal
Infections at University of Liverpool in partnership with the UK Health Security Agency (UKHSA), in
collaboration with University of Warwick. The views expressed are those of the author(s) and not
necessarily those of the NIHR, the Department of Health and Social Care or the UK Health Security
Agency.

Consent for publication: Not applicable
Ethics: The protocol for this study was submitted and approved by the CPRD Independent Scientific
Advisory Committee (ISAC). CPRD obtains annual rolling ethical approval (reference number
05/MRE04/87) and no additional ethical approval was required for this project which meets ISAC
requirements. The data was accessed via the University of Liverpool CPRD license agreement.
Availability of data and materials: Data from this study is not available from the authors. Study data
is available through formal request from CPRD.
Data sharing statement: The datasets used in this study were extracted from CPRD following CPRD
approval of the study protocol and through a data sharing agreement between University of
Liverpool and CPRD. The same dataset is available from CPRD. The authors are not authorised to
share the datasets and are obliged to destroy the datasets according to the data sharing agreement
between University of Liverpool and CPRD.

<u>References</u>

1.   Walker JL, Andrews NJ, Amirthalingam G, Forbes H, Langan SM, Thomas SL. Effectiveness of
327   herpes zoster vaccination in an older United Kingdom population. Vaccine. 2018
328   Apr;36(17):2371–7.

329   2.   Aaby P, Martins CL, Garly ML, Bale C, Andersen A, Rodrigues A, et al. Non-specific effects of
330   standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised
331   controlled trial. BMJ. 2010 Nov 30;341(nov30 2):c6495–c6495.

332   3.   Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, et al. Randomized Trial of BCG
333   Vaccination at Birth to Low-Birth-Weight Children: Beneficial Nonspecific Effects in the
334   Neonatal Period? The Journal of Infectious Diseases. 2011 Jul 15;204(2):245–52.

335   4.   de Castro MJ, Pardo-Seco J, Martinón-Torres F. Nonspecific (Heterologous) Protection of
336   Neonatal BCG Vaccination Against Hospitalization Due to Respiratory Infection and Sepsis. Clin
337   Infect Dis. 2015 Jun 1;60(11):1611–9.

338   5.   Sørup S, Benn CS, Poulsen A, Krause TG, Aaby P, Ravn H. Live vaccine against measles, mumps,
339   and rubella and the risk of hospital admissions for nontargeted infections. JAMA. 2014 Feb
340   26;311(8):826–35.

341   6.   Bardenheier BH, McNeil MM, Wodi AP, McNicholl JM, DeStefano F. Risk of Nontargeted
342   Infectious Disease Hospitalizations Among US Children Following Inactivated and Live Vaccines,
343   2005–2014. Clinical Infectious Diseases. 2017 Sep 1;65(5):729–37.

344   7.   Goodridge HS, Ahmed SS, Curtis N, Kollmann TR, Levy O, Netea MG, et al. Harnessing the
345   beneficial heterologous effects of vaccination. Nature Reviews Immunology. 2016
346   Jun;16(6):392–400.

347   8.   Lee S, Lee K, Oh J, Kim HJ, Son Y, Kim S, et al. Live zoster vaccination and cardiovascular
348   outcomes: a nationwide, South Korean study. European Heart Journal. 2025 May 5;ehaf230.

349   9.   Eyting M, Xie M, Michalik F, Heß S, Chung S, Geldsetzer P. A natural experiment on the effect of
350   herpes zoster vaccination on dementia. Nature. 2025 Apr 2;1–9.

351   10.   Stoye G, Warner M, Zaranko B. The past and future of UK health spending [Internet]. Institute
352   for Fiscal Studies; 2024 [cited 2025 Sep 9]. Available from: https://ifs.org.uk/publications/past-
353   and-future-uk-health-spending

354   11.   Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al. Data resource profile:
355   Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019 Dec;48(6):1740–1740g.

356   12.   Weinberg GA, Szilagyi PG. Vaccine Epidemiology: Efficacy, Effectiveness, and the Translational
357   Research Roadmap. The Journal of Infectious Diseases. 2010 Jun 1;201(11):1607–10.

358   13.   UKHSA UHSA. Immunisation against infectious disease. The Green Book [Internet]. GOV.UK.
359   2021 [cited 2025 Aug 12]. Available from:
360   https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-
361   green-book

362   14.   Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration
363   and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol
364   Drug Saf. 2005 Jul;14(7):443–51.

365   15.   Torisson G, Rosenqvist M, Melander O, Resman F. Hospitalisations with infectious disease
366   diagnoses in somatic healthcare between 1998 and 2019: A nationwide, register-based study in
367   Swedish adults. The Lancet Regional Health – Europe [Internet]. 2022 May 1 [cited 2025 Aug
368   1];16. Available from: https://www.thelancet.com/journals/lanepe/article/PIIS2666-
369   7762(22)00036-9/fulltext

370   16.   Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the
371   Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using
372   data from 6 countries. Am J Epidemiol. 2011 Mar 15;173(6):676–82.

373   17.   Booth HP, Prevost AT, Gulliford MC. Validity of smoking prevalence estimates from primary
374   care electronic health records compared with national population survey data for England,
375   2007 to 2011. Pharmacoepidemiology and Drug Safety. 2013;22(12):1357–61.

376   18.   Raleigh V. What is happening to life expectancy in England? [Internet]. The King's Fund. 2022
377   [cited 2023 Sep 12]. Available from: https://www.kingsfund.org.uk/publications/whats-
378   happening-life-expectancy-england

379   19.   Inns T, Fleming KM, Iturriza-Gomara M, Hungerford D. Paediatric rotavirus vaccination, coeliac
380   disease and type 1 diabetes in children: a population-based cohort study. BMC Medicine. 2021
381   Jun 29;19(1):147.

382   20.   Therneau T, Crowson C, Atkinson E. Using Time Dependent Covariates and Time Dependent
383   Coefficients in the Cox Model [Internet]. ResearchGate. 2024 [cited 2025 Jul 24]. Available
384   from:
385   https://www.researchgate.net/publication/265041278_Using_Time_Dependent_Covariates_a
386   nd_Time_Dependent_Coefficients_in_the_Cox_Model

387   21.   Bozdogan H. Model selection and Akaike's Information Criterion (AIC): The general theory and
388   its analytical extensions. Psychometrika. 1987 Sep 1;52(3):345–70.

389   22.   Gallagher AM, Dedman D, Padmanabhan S, Leufkens HGM, Vries F de. The accuracy of date of
390   death recording in the Clinical Practice Research Datalink GOLD database in England compared
391   with the Office for National Statistics death registrations. Pharmacoepidemiology and Drug
392   Safety. 2019;28(5):563–9.

393   23.   Taquet M, Dercon Q, Todd JA, Harrison PJ. The recombinant shingles vaccine is associated with
394   lower risk of dementia. Nat Med. 2024 Oct;30(10):2777–81.

395   24.   Kleinnijenhuis J, Quintin J, Preijers F, Benn CS, Joosten LAB, Jacobs C, et al. Long-Lasting Effects
396   of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity.
397   JIN. 2014;6(2):152–8.

398   25.   Kleinnijenhuis J, Quintin J, Preijers F, Joosten LAB, Jacobs C, Xavier RJ, et al. BCG-induced
399   trained immunity in NK cells: role for non-specific protection to infection. Clin Immunol. 2014
400   Dec;155(2):213–9.

401   26.   Sei JJ, Cox KS, Dubey SA, Antonello JM, Krah DL, Casimiro DR, et al. Effector and Central
402   Memory Poly-Functional CD4+ and CD8+ T Cells are Boosted upon ZOSTAVAX® Vaccination.

403   Frontiers in Immunology [Internet]. 2015 [cited 2023 Sep 15];6. Available from:
404   https://www.frontiersin.org/articles/10.3389/fimmu.2015.00553

Table 1: Baseline characteristics of comparison groups			
	No shingles vaccine exposure n=165 666 (%)	Shingles vaccine exposure n=209 382 (%)	Comparison Test*
Male sex	87 069 (52·6)	110 335 (52·7)	P=0·399
Age (median, IQR)	72·2 [69·5, 74·2]	69·5 [69·5, 72·2]	P<0·001
Comorbid	104 650 (63·1)	122 731 (58·6)	P<0·001
Cardiovascular disease	25 188 (15·2)	23 580 (11·3)	P<0·001
Respiratory disease	30 708 (18·5)	33 682(16·1)	P<0·001
Liver disease	1616 (1·0)	1243 (0·6)	P<0·001
Diabetes mellitus	39 016 (23·6)	47 470 (22·7)	P<0·001
Solid organ malignancy	31 055 (18·7)	37 710 (18·0)	P<0·001
Dementia	5106 (3·1)	2638 (1·3)	P<0·001
Connective tissue disease	3144 (1·9)	3914 (1·9)	P=0·524
Peptic ulcer disease	7108 (4·3)	7379 (3·5)	P<0·001
Updated Charlson Index of Comorbidity** (median, IQR)	4·0 [3·0, 5·0]	3·00 [3·0, 4·0]	P<0·001
Index of Multiple Deprivation quintile***			
1 (least deprived)	43 155 (26·0)	61 070 (29·2)	
2	37 356 (22·5)	51 506 (24·6)	
3	33 058 (20·0)	41 834 (20·0)	
4	28 467 (17·2)	32 213 (15·4)	
5 (most deprived)	23 630 (14·3)	22 759 (10·9)	P<0·001
Geographical Region			
North East	7781 (4·7)	9475 (4·5)	
North West	29 247 (17·7)	34 542 (16·5)	
Yorkshire & The Humber	6517 (3·9)	8721 (4·2)	
East Midlands	3785 (2·3)	5796 (2·8)	
West Midlands	31 145 (18·8)	41 012 (19·6)	
East of England	9885 (6·0)	14 131 (6·7)	
South West	23 772 (14·3)	30 302 (14·5)	
South Central	20 620 (12·4)	26 828 (12·8)	
London	19 569 (11·8)	20 283 (9·7)	
South East Coast	13 324 (8·0)	18 271 (8·7)	P<0·001
Ever having smoked	118 079 (71·3)	147 695 (70·5)	P<0·001
Rate of attendance at doctor's surgery in two years preceding year of study entry (median, IQR)****	0·16 [0·10, 0·26]	0·16 [0·10, 0·24]	P<0·001
Average number of influenza vaccinations per year (median, IQR)*****	1·03 [0·67, 1·03]	1·03 [0·86, 1·11]	P<0·001
PPV23 vaccination prior to study entry	139 980 (84·5)	171 851 (82·1)	P<0·001
Herpes-zoster associated disease in 5 years prior to study entry	5953 (3·6)	7718 (3·7)	P=0·132
*chi-squared or Wilcoxon Rank Sum; **Quan et al (2011); ***for n=299 participants with missing index of multiple deprivation, the corresponding medical practice's index of multiple deprivation was substituted; **** = number of weeks in which participant attended their medical practice in two years preceding year of entry to study / total of 104 weeks; ***** = number of influenza immunisation events / participant's person-time in years, IQR = interquartile range, PPV23 = pneumococcal polysaccharide vaccine			

Table 2: Rate of death and hospitalisation and effectiveness of shingles vaccine exposure				
			Hazard estimation by Cox proportional hazards model	Hazard estimation at median follow-up timepoint by time-varying coefficient model
	No shingles vaccine exposure	Shingles vaccine exposure	Crude HR (95% CI)	Crude HR (95% CI)
			Adjusted HR (95% CI)*[†]	Adjusted HR (95% CI)*
Death per 1000 pyo (no. outcomes/total pyo)	21·2 n=21 976/1 034 560	14·6 n=8382/575 300	0·55 (0·54-0·57)	0·46 (0·43-0·50)
			0·68 (0·67-0·70)	0·67 (0·62-0·72)
Hospitalisation per 1000 pyo (no. outcomes/total pyo)	212 n=154 828/731 568	219 n=74 340/339 860	0·96 (0·95-0·97)	1·01 (0·99-1·03)
			0·99 (0·98-1·00)	1·04 (1·02-1·07)
Infection-associated hospitalisation. per 1000 pyo (no. outcome/total pyo)	51·7 n=49 427/956 243	42·5 n=22 337/525 075	0·72 (0·71-0·73)	0·70 (0·67-0·73)
			0·83 (0·81-0·84)	0·82 (0·79-0·86)
*adjusted for age, sex, ever having smoked, index of multiple deprivation quintile, mean influenza vaccinations per year, updated Charlson comorbidity score, attendance rate at doctor's surgery in two years preceding year of study entry, time-varying covariate for pneumococcal polysaccharide vaccine exposure, [†] with random intercept for practice, pyo=person-years of observation, HR=hazard ratio, 95% CI = 95% confidence interval				

409   Figure 1: Survival and hospitalisation-free survival in live shingles vaccine exposed and unexposed adults aged 70 years and
410   over

413   Figure 2: Hazard associated with live shingles vaccine exposure over follow-up time

414
415   *Time-varying coefficient model of hazard associated with live shingles vaccine exposure over follow-up time adjusted for*
416   *age, sex, smoking, deprivation quintile, influenza & PPV23 vaccine exposure, comorbidity score, attendance rate at doctor's*
417   *surgery using cubic b-splines and yearly internal knots. Red solid line=median follow-up time.*